When Medicare was created in 1965, lawmakers explicitly excluded weight loss drugs from coverage—a decision that has stood for six decades. This spring, that prohibition ends for millions of Americans as a landmark pilot program launches, offering GLP-1 medications like Novo Nordisk's Wegovy and Eli Lilly's upcoming oral obesity pill for just $50 per month.

The program, negotiated directly between the Trump administration and pharmaceutical giants Eli Lilly and Novo Nordisk in November 2025, represents one of the most significant expansions of Medicare benefits in recent memory. An estimated 10 million seniors could qualify, potentially transforming both their health outcomes and their finances.

Who Qualifies for Coverage

The pilot program isn't universal Medicare coverage for weight loss. Instead, it targets seniors with the greatest medical need—those whose obesity creates or exacerbates serious health conditions.

To qualify, Medicare beneficiaries must meet one of these criteria:

  • Severe obesity: Body mass index (BMI) of 35 or higher
  • Obesity with cardiovascular disease: BMI of 30 or higher plus diagnosed heart disease, history of heart attack, or stroke
  • Obesity with kidney disease: BMI of 30 or higher plus chronic kidney disease stage 3 or higher
  • Obesity with type 2 diabetes: BMI of 30 or higher plus diabetes requiring medication management

Notably, the program does not cover seniors who are simply overweight (BMI 25-29.9) without comorbidities, nor those seeking weight loss for purely cosmetic reasons. The medical necessity requirement reflects the legal workaround that made coverage possible.

The $50 Monthly Copay

For those who qualify, the financial relief is substantial. Without coverage, GLP-1 medications typically cost between $1,000 and $1,500 per month at retail prices. Even with the discount programs both companies have offered, many seniors have paid $400 or more monthly out of pocket.

Under the pilot program:

  • Monthly copay: $50 for all approved uses, regardless of specific medication
  • Covered drugs: Injectable Wegovy, injectable Zepbound, and oral versions as they receive FDA approval
  • No prior authorization hurdles: The standard Medicare Part D prior authorization process is streamlined for pilot participants
  • No quantity limits: Participants can receive full therapeutic doses without artificial restrictions

For a senior currently paying $1,200 monthly for Wegovy, the pilot program represents savings of nearly $14,000 annually—a life-changing sum for many on fixed incomes.

How the Deal Came Together

The Trump administration announced the agreements with Eli Lilly and Novo Nordisk on November 6, 2025, framing them as a major healthcare policy victory. In exchange for reduced Medicare prices and participation in the pilot, both companies secured significant benefits:

  • Manufacturing commitments: Novo Nordisk pledged $10 billion in new U.S. manufacturing investment; Eli Lilly committed $27 billion
  • Tariff exemptions: Both companies received relief from pharmaceutical tariffs on imported ingredients
  • TrumpRx distribution: Their medications will be featured on the administration's direct-to-consumer drug purchasing website
  • Market expansion: Medicare coverage could dramatically increase their addressable market

Critics have noted that the deal essentially bypasses Congress, which would normally need to change the law prohibiting Medicare weight loss drug coverage. The administration is using a "demonstration project" authority that allows temporary programs without legislative approval.

"This isn't a permanent fix—it's a pilot that could end if the next administration decides to cancel it. But for seniors who qualify, that's a risk worth taking given the immediate savings."

— Healthcare policy analyst at the Kaiser Family Foundation

The Oral Pill Factor

The pilot's timing coincides with a revolution in obesity drug delivery. Novo Nordisk's oral Wegovy pill received FDA approval in December 2025 and hit pharmacies in January at $149 monthly for starting doses and $299 for maintenance doses. Eli Lilly's oral competitor, orforglipron, is expected to receive approval within weeks.

For Medicare beneficiaries, oral options eliminate the need for weekly self-injections—a significant barrier for many older patients with dexterity issues or needle phobia. Under the pilot:

  • Starting doses: $149 monthly through TrumpRx, or potentially $50 if qualifying for Medicare pilot
  • Maintenance doses: $50 monthly copay through the Medicare pilot program
  • No injection required: Daily pill format similar to taking any other medication

Eli Lilly CEO David Ricks noted that Medicare coverage "will change the game" for their upcoming pill launch, predicting rapid adoption once coverage is available.

How to Prepare Now

The pilot program is expected to launch in late spring 2026, with some Part D plans beginning enrollment in April. Seniors who think they may qualify should take several steps now:

1. Confirm your eligibility: Review your BMI and medical conditions against the qualification criteria. Your primary care physician can help determine if you meet the medical necessity requirements.

2. Check your Part D plan: The pilot is voluntary for Medicare prescription drug plans. Contact your plan to ask whether they will participate and when enrollment opens.

3. Gather documentation: You'll likely need recent lab work confirming diagnoses, current weight and height measurements, and documentation of any obesity-related conditions.

4. Discuss with your doctor: GLP-1 medications aren't appropriate for everyone. Side effects can include nausea, vomiting, and rare but serious complications. A frank conversation about risks and benefits is essential.

The Broader Implications

If the pilot succeeds, it could pave the way for permanent Medicare coverage of obesity medications—potentially costing hundreds of billions over the coming decade but also potentially saving even more through reduced diabetes, heart disease, and other obesity-related conditions.

For now, the pilot represents a rare moment of bipartisan policy alignment. Both parties have expressed interest in addressing obesity, which affects over 40% of American adults and drives enormous healthcare costs. Whether this pilot becomes permanent policy will depend on its demonstrated outcomes—and the political will of future administrations.

For the 10 million seniors who may qualify, the spring pilot launch offers something they've never had: affordable access to medications that could add years to their lives and improve the quality of those years. After six decades of exclusion, Medicare is finally entering the obesity treatment era.